Although these TNF-α inhibitors confer high efficacy against a rash, background factors of patients predicting treatment responses, such as age, sex, body mass index (BMI), disease duration, baseline psoriasis area and severity index (PASI), presence or absence of bio-switch or arthritis, have not been precisely investigated. This evidence concerns the gene TNF and arthritic joint disease.